FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
JTC Team and Virtual Investor Co. are paid consultants to Adolore Biotherapeutics, Inc; Aeterna Zentaris, Inc; AIM ImmunoTech, Inc; American Resources Corporation; Autonomix Medical Inc.; Ceapro, Inc; CNS Pharmaceuticals, Inc; enVVeno Medical Corporation; Exxel Pharma, Inc; GRI Bio, Inc; iTolerance, Inc; Kaida BioPharma, Inc; Moleculin Biotech, Inc; Outlook Therapeutics, Inc.; Palisade Bio; Sonnet BioTherapeutics, Inc.; TuHura Biosciences, Inc.; and Xenetic Biosciences, Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included on this website shall not be construed as an offer to purchase securities of the applicable companies. Interested parties are responsible for conducting their own due diligence and are encouraged to review the companies’ websites and the SEC website for the latest information and filings on each company.
CONTACT US
SIGN UP FOR EMAIL ALERTS